

Reference:	FOI.5928.21
Subject:	Neurology patient treatments
Date of Request:	30 April 2021

Requested:

Could you please answer the following three questions:

- How many patients have been treated with the following drugs in the past 4 months:
 - Ajovy (fremanezumab) - any disease
 - Aimovig (erenumab) - any disease
 - Emgality (galcanezumab) - any disease
 - Botulinum Toxin (i.e. Botox, Dysport, Xeomin) - for migraine ONLY
- How many patients have been treated in the past 4 months for the following conditions:
 - Chronic migraine (15+ headache days per month)
 - Episodic migraine (4-14 headache days per month)
- In case your trust does not treat chronic/episodic migraine, can you please tell me which trust you refer these patients to?

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with all of the information requested, as it is estimated that the cost of answering your request would exceed the “appropriate level” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. The “appropriate level” represents the estimated cost of one person spending 18 hours (or 2 ½ working days) in determining whether the UHB holds the information, as well as locating, retrieving and extracting the information.

In order to provide you with the requested information, the UHB would need to undertake a manual trawl of all neurology patient records, to identify any information that fulfils your request.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under section 16 of the FoIA, we are required, as a public authority, to provide advice and assistance so far as it is reasonable, to individuals who have made a request under FoIA. Therefore, the UHB provides, within the table below, the number of patients treated for any condition with the listed medications provided at question 1, during the period 1 January to 30 April 2021.

Medication	Number
Ajovy (fremanezumab)	*
Aimovig (erenumab)	0
Emgality (galcanezumab)	0
Botulinum Toxin	65

Where the figure in the table has been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low number (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 2018/ General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.